AMD Drugs Market Size, Share, Growth Analysis, and Report 2024-2031

AMD Drugs Market was valued at US$ 9,717.64 million in 2023 and is estimated to reach US$ 15,903.86 million by 2031, growing at a CAGR of 7.26% during the forecast period (2024-2031).

The AMD (Age-related Macular Degeneration) drugs market refers to the sector of the pharmaceutical industry that deals with the development, production, and distribution of medications used to treat or manage Age-related Macular Degeneration. AMD is a progressive eye condition that affects the macula, the part of the retina responsible for sharp, central vision. It is a leading cause of vision loss in older adults.

Get a Free Sample Research PDF: https://www.datamintelligence.com/download-sample/amd-drugs-market

Market Dynamics:

The increasing number of novel product launches and the rising regulatory approvals will drive market growth.

The global market for age-related macular degeneration (AMD) drugs is experiencing significant growth due to several factors. The increasing geriatric population and a rise in AMD cases are major drivers. Additionally, the surge in novel product launches and ongoing clinical trials contribute to this growth.
For example, in August 2022, Kodiak Sciences Inc. reported positive outcomes from the Phase 3 BEACON study of its new antibody biopolymer conjugate, tarcocimab tedromer (KSI-301: tarcocimab). The drug achieved the primary endpoint of non-inferior visual acuity change at 24 weeks compared to aflibercept in patients with macular edema.

Further boosting the market, advancements in technology, increased funding, and regulatory approvals are fueling demand for AMD drugs. Notably, in October 2021, Genentech received FDA approval for Susvimo (ranibizumab injection), administered via an intravitreal ocular implant. This treatment is for patients with neovascular or wet AMD who have previously responded to at least two anti-vascular endothelial growth factor injections.

Segment Covered in the AMD Drugs Market:

By Product Type: Wet AMD, Dry AMD.

By Drug Type: Lucentis, Eylea, Avastin, Others.

By Route of Administration: Intravenous, Intravitreal.

Get Customization in the report as per your requirements: https://www.datamintelligence.com/customize/protein-labeling-market

Key players involved in AMD Drugs Market:

• Bayer HealthCare LLC
• F. Hoffmann-La Roche Ltd.
• Regeneron Pharmaceuticals, Inc.
• Novartis AG
• Pfizer Inc.
• Kubota Pharmaceutical Holdings Inc.
• AbbVie Inc.
• Kodiak Sciences
• Genentech Inc., Roche Group Member
• Regenxbio Inc.

Related Reports:

Endometriosis Drug Market: https://www.datamintelligence.com/research-report/endometriosis-drug-market

Oral Cavity Cancer Market: https://www.datamintelligence.com/research-report/oral-cavity-cancer-market

Pharmacovigilance Market: https://www.datamintelligence.com/research-report/pharmacovigilance-market

Product Portfolio:

Eylea

Eylea is an approved anti-VEGF (vascular endothelial growth factor) therapy known for its long-lasting efficacy. Clinical trials have demonstrated that Eylea can be administered with a Treat and Extend (T&E) dosing regimen, successfully extending treatment intervals up to approximately 16 weeks. This extended interval provides sustained anti-VEGF activity, making Eylea a valuable option in managing conditions associated with VEGF.

Regional Analysis:

The AMD Drugs Market report focuses on six major regions: North America, Latin America, Europe, Asia Pacific, the Middle East, and Africa. The report offers detailed insight into new product launches, new technology evolutions, innovative services, and ongoing R&D. The report discusses a qualitative and quantitative market analysis, including PEST analysis, SWOT analysis, and Porter's five force analysis. The AMD Drugs Market report also provides fundamental details such as raw material sources, distribution networks, methodologies, production capacities, industry supply chain, and product specifications.

Contact Us -
Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com

About Us -
DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.

Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.

This release was published on openPR.